Thyroid cancer is the most common endocrine malignancy. With the annually increasing number, approximately 62,980 estimated thyroid cancers are newly diagnosed in the United States in 2014[@b1], more than 90% of which are differentiated thyroid cancers (DTC). DTC usually is subdivided into papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). Although it has been reported that DTC presents a relatively excellent prognosis previously[@b2], about 10% of the patients still die of this cancer[@b3][@b4]. Therefore, different scoring systems have been created in DTC for prognosis stratification aiming to identify an optimal therapy for high-risk patients to reduce disease recurrence[@b5][@b6]. Age, in particular, is considered to be the most important prognostic factor as demonstrated by the majority of current risk stratification systems[@b7][@b8]. The new tumor-node-metastasis(TNM)classification[@b9][@b10] is to our knowledge one of the most common systems adopting an age cutoff of 45 years to stratify the patients in high- and low-risk groups for cancer-specific mortality. Conversely, a series of different setups such as EORTC(1979), AGES (1987), AMES (1988), DAMES (1992), MACIS (1993) consider age as a continuous factor that affecting the prognosis without any stratification[@b11][@b12]. The controversies on how to categorize ages for predicting prognosis in DTC derive from several studies suggest the relationship between the age and mortality is represented by an exponential function rather than a categorical variable[@b13]. The present study is to elucidate the prognostic implication of age in patients with DTC as reported by the SEER Program from 2004 to 2012. Specifically, we compared the survival of patients with different age ranges aiming to accurately determine the relationship between age and outcome of DTC patients.

Methods
=======

We extracted data from the SEER cancer registry to conduct this study. SEER, a population-based registry sponsored by the National Cancer Institute, collects information on cancer incidence and survival from 17 population-based cancer registries, including approximately 28% of the U.S. population[@b14]. SEER data contains no identifiers and is publicly available for studies on cancer-based epidemiology and health policy. The National Cancer Institute's SEER\*Stat software (Surveillance Research Program, National Cancer Institute SEER\*Stat software, [www.seer.cancer.gov/seerstat](http://www.seer.cancer.gov/seerstat) Version 8.1.2) was used to identify patients whose pathological diagnosis was DTC between 2004 and 2012. Patients with surgical therapy for DTC as the only malignancy or the first one of more malignancies were included. Histology types were limited to papillary carcinoma (8050/3, 8052/3, 8340/3, 8341/3, 8342/3, 8343/3, 8344/3, 8347/3) and follicular adenocarcinoma (8330/3, 8331/3, 8332/3, 8335/3, 8346/3). The histology classification is derived from ICD-0-3 SEER site/histology validation list (2015). Other patients were excluded.

Ethics statement
----------------

This study was in compliance with the Helsinki Declaration. An independent ethics committee/institutional review board at Fudan University Shanghai Cancer Center approved our study. The methods were carried out in accordance with the approved guidelines in this study. Data released from the SEER database do not require informed patient consent because they contain no identifiers and were publicly available. We have got permission to access the research data file in the SEER program by National Cancer Institute, USA and the reference number was 13579-Nov 2014.

Clinicopathological variable assessment and statistical analysis
----------------------------------------------------------------

The variable of "age" refers to "age at diagnosis" when not otherwise specified. Young patients (≤20 yr) with DTC were grouped together because there was a relatively small number, the rest of the patients were stratified into 10-year age groups. Compared to dichotomizing patients into younger (\<45 yr) *vs.* older group (≥45 yr), the application of 10-year age ranges allowed for a more detailed analysis of clinicopathologic features and treatment by age. The endpoint of the present study was DTC cause-specific survival (CSS) which was calculated from the day of diagnosis to the day of cancer-specific death and was shown as "SEER cause-specific survival" in the SEER database. Overall survival (OS) was calculated from the day of diagnosis to the day of death, which was indicated as "Vital Status" in the SEER database. Race, sex, tumor grade, histological type, summary stage, TNM stage, radiation, CSS and OS were assessed. We followed the guidance of the 2010 TNM classification of American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC)[@b9][@b10].

Chi-square (χ2) test was used to evaluate the independent variables. Survival rate was generated using Kaplan-Meier curve, and the differences were compared with the log-rank test. Multivariate Cox regression models were used for analysis of risk factors of survival. The 95% confidence intervals (CIs) for proportions were calculated. The nonlinear effect of age on the hazard ratio (HR) of DTC-specific mortality was assessed using quintic polynomial regression, with the R^2^ reported. *P* \< 0.05 was considered statistically significantly. Statistical analysis was performed using SPSS for Windows 13.0 computer software (SPSS Inc., Chicago, IL).

Results
=======

Baseline characteristics and comparison among groups according to age
---------------------------------------------------------------------

We identified 51,061 eligible patients with DTC in SEER database between 2004 and 2012. There were 1,382 patients in the young (≤20) group that representing the smallest number of subjects; the majority of patients was classified into 31--40 (n = 10,207), 41--50 (n = 12,624), and 51--60 (n = 11,237) groups ([Table 1](#t1){ref-type="table"}). The proportions of races and papillary subtype in each group were comparable with slight variations ([Table 1](#t1){ref-type="table"}, [Fig. 1a](#f1){ref-type="fig"}). The proportion of patients receiving radiation gradually decreased with age, however, the proportion of risk factors such as male gender, grade III/IV and summary stage of distant had increasing trend in the entire cohort ([Table 1](#t1){ref-type="table"}, [Fig. 1a](#f1){ref-type="fig"}). The overall death events increased from 0.3% in the young group to 16.2% in the oldest group and this phenomenon was also observed for cancer specific deaths within overall death events ([Table 1](#t1){ref-type="table"}, [Fig. 1b](#f1){ref-type="fig"}).

The impact of age on survival in DTC
------------------------------------

The mean length of follow-up was 45.7 months (SD = 30.5), with a range of 0--107 months. The OS and CSS rate was 96.5% and 98.8% at 5 years, 93.8% and 98.1% at 8 years from the time of diagnosis. Although patients with DTC showed relatively favorable prognosis, we observed that there was continued worsening in OS and CSS rates with increasing age by Kaplan--Meier curves, both being poorest in elderly(≥71) groups ([Fig. 2a,b](#f2){ref-type="fig"}). The results of the univariate Cox proportional hazard regression analysis investigating the differences in survival rates among groups confirmed the worsening trends of OS and CSS with respect to aging ([Table 2](#t2){ref-type="table"}). To determine how strongly increasing age was associated with mortality relative to other known risk factors in DTC, we performed multivariate Cox regression analysis. The risk of mortality increased with increasing age: on the one hand, patients in the 41--50, 51--60, 61--70 and ≥71 groups exhibited a significantly greater risk of overall mortality than the young group; on the other hand with respect to cancer-specific mortality, higher risk began to be observed until age older than 60. The risk of cancer-specific death was significantly higher in 61--70 and ≥71 age group, who were about 7.5 and 13.5 times more likely to die of cancer than young (≤20) age group. The plots of HRs in subgroups according to different age ranges showed that hook-shaped curves and HRs started to apparently increase in the above 40 years age group for OS and 60 years age group for CSS ([Fig. 3a,b](#f3){ref-type="fig"}). An age of 60 years was tested by performing receiver operating characteristic (ROC) analysis for a meaningful separation of predicting cancer-specific death, the result suggested that an area under the curve was 0.831 (*p* = 0.001, 95% CI 0.815--0.848) with the sensitivity (67.1%) and specificity (80.9%).

The predictability of age on prognosis in histologic subtypes of thyroid cancer
-------------------------------------------------------------------------------

Of note, this series comprised of a dominant proportion of papillary thyroid cancer (PTC, 94.2%) and a low proportion of follicular thyroid cancer (FTC, 5.8%). The composition of histologic subtypes for PTC and FTC were shown in [Fig. 4a,b](#f4){ref-type="fig"}. In PTC and FTC patients, the predominating histologic variants were follicular variant and minimally invasive, respectively. The variants considered to carry a poorer prognosis such as solid, tall-cell, and poorly differentiated were rare in this series, which was different from other systems incorporating histologic variants in the prognostic model[@b15][@b16]. Although PTC and FTC were staged in the same way in current systems, the results of univariate analysis demonstrated highly significant differences of death risks between the different groups (PTC *vs.* FTC, [Table 2](#t2){ref-type="table"}). Therefore, we tested the predictability of age on prognosis in subtypes of DTC, respectively. Similarly, increasing was associated with the worsening trends of cancer-specific survivals in both groups. However, the trends of decreasing CSS were not statistically significant among the different age groups of patients with PTC, or patients with FTC until they were older than 70 years ([Supplemental Fig. 1a,b](#S1){ref-type="supplementary-material"}).

The other risk factors associated with mortality in DTC
-------------------------------------------------------

In multivariate analysis, the results also suggested a series of factors that were previously demonstrated to be important in predicting poor prognosis in DTC patients, such as male gender, higher tumor grade (III/IV) and cancer stage ([Table 2](#t2){ref-type="table"}). In particular, the adjuvant radiation therapy had improved the OS but not CSS rate in the entire cohort according to the multivariate analysis ([Table 2](#t2){ref-type="table"}).

Discussion
==========

Thyroid cancer, especially DTC, has presented an obviously increasing incidence all over the world. Due to the excellent post-treatment outcome, it is difficult to make a randomized clinical trial to study these cancers. Most current staging evaluating the risk of cancer-specific death in DTC are developed by multivariate analysis of a specified patient population, there are many controversies when applying a certain system to a different patient population[@b17]. Age at diagnosis is considered to be one of the established risk factors for stratification[@b18][@b19][@b20], however, the rationale for how to define the relationship between mortality and age needed to be clarified in DTC. In the present study, we divided DTC patients into subgroups with a 10-year intervals to assess the differences of clinicopathologic features and oncological outcomes among them; we found that the increasing age was associated with the high proportions of risk factors conferring unfavorable prognosis (such as male gender, grade III/IV and summary stage of distant metastases) and high risk of death events referring to both overall and cancer-specific reasons. The survival analysis confirmed the results and suggested that CSS of patients with DTC increased significantly until they were elder than 60 yr compared to the young groups.

Although DTC affects young adults with a significantly increasing incidence occurring between ages 25--54 years, the incidence appears to be rising in older people (≥65 years) simultaneously[@b21]. Similar to unfavorable histopathological features, it has been demonstrated that old age is a predictive factor for CSS in patients with DTC. The results of the present study repeatedly indicated that OS and CSS deteriorated with aging in DTC patients, and extremely worst among elderly patients (\>70 years). The increased aggressiveness with the age gradient corresponded to a variety of factors, such as higher proportion of male gender, advanced tumor grade, follicular subtype, advanced tumor stage (Summary Stage and AJCC 7^th^ Stage), which were all proved to be independent risk factors for prognosis in univariate analysis. Given the substantial diversity of clinicopathologic features among different age gradients, it has been suggested that DTC may develop "separate forms" in the progression of aging. Additionally, we found that the ratio of patients who received radiation therapy decreased with age, and it has been reported that the effectiveness of radioiodine therapy decreases in the elder group due to the fact that the uptake of radioiodine is age-dependent[@b22]. This may be another reason why DTC patients have deteriorated prognosis with aging.

Liang *et al.* reviewed 9 staging systems derived from DTC series, found that 5 of them included age as a contributor for risk classification[@b23]. Most of stratification systems considered DTC patients under a certain age cutoff as less risk than those who were older. For example, an age of 45 was the cutoff point for continuous variables in Memorial Sloan Kettering (Grade, Age, Metastasis, Extent, Size or GAMES) and AJCC/UICC systems[@b9][@b24], while 50 years of age was applied in University of Alabama and M.D. Anderson (UAB&MDA) system[@b25]. Thus, there is a lack of consensus among the staging systems regarding to the age threshold to be adopted. On the basis of the present study, we found that young patients (≤20 yr) had a favorable CSS rate, compared to the young group, the DSS for different age groups did not show a statistically significant decrease until the age of 60 years when the first significant drop was observed. Multivariate analysis by the Cox proportional HR model confirmed that the importance of age as an independent risk determinant became evident only after the age of 60 years and the subset analysis of patients above 60 years showed obviously increased cancer-specific mortality compared to young group.

The finding that each age decade was independently associated with a worse prognosis starting at 60 years was similar to that of recent study[@b13]. This suggests that the mortality rate in patients younger than 60 years is better, and the currently practiced cut off age such as 45 or 50 year seems to be lower. The dominating proportion in this cohort for PTC (94.2%), which is the less invasive subtype of DTC compared with FTC[@b26], and the high constitution of papillary thyroid microcarcinoma (PTMC, [Fig. 4a](#f4){ref-type="fig"}) with indolent behaviors, may account for the reason why a great number of staging systems including the current TNM system intended for DTC used relatively lower cutoff ages for stratifying patients into different risk categories behavior[@b27][@b28].

Interestingly, the OS rate continues to fall with the age gradient, but significantly starting at 40 years compared to the young group. Unlike young populations with thyroid disease, older patients often have multiple complex illnesses coincident with their thyroid disease, some of which may be lethal such as cardiovascular disease, respiratory disease and other malignant tumors[@b29]. Recognition of these disorders will lead to better evaluation and appropriate therapy in elderly patients.

Except for the consideration of age and other clinicopathologic factors such as male gender, higher tumor grade (III/IV) and cancer stage when evaluating the risk of mortality in DTC, current studies suggest that complete surgical resection and postoperative radiation therapy are comparatively significant prognostic factor, especially in high risk patients[@b30]. Unfortunately, the details on surgical and radiation therapies were incomplete in the process of using the SEER database for survival analysis. However, given the aggressive features and decreased prognosis associated with aging, the appropriate surgery for initial management is of great importance for the elderly patients. To find out whether treatment could possibly affect the relative predictability of prognosis in different age patients, a comparative study with enough length of follow-up is necessary to be conducted based on subgroup analysis including relatively homogeneous DTC patients but with different procedures of thyroidectomy followed by radiation therapy or not.

In light of the results from present study, we found DTC with aging generally showed more aggressive features and decreased prognosis compared with younger adults. After the age of 60 years, the CSS was found to fall significantly in the older patients. Since the influence of age on prognosis is affirmed, clinicians who see older patients with DTC need to be aware of their poorer prognosis, especially older than 60 years.
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###### Characteristics of DTCs from SEER Database by Age.

                                             ≤20         21--30       31--40        41--50        51--60        61--70        ≥71       P value
  -------------------------------------- ------------ ------------ ------------- ------------- ------------- ------------ ------------ ---------
  Variable                                (n = 1382)   (n = 5626)   (n = 10207)   (n = 12624)   (n = 11237)   (n = 6492)   (n = 3493)       
  Race                                                                                                                                 
   Black                                      54          242           485           702           648          343          177        0.001
   %                                         3.9          4.3           4.8           5.6           5.8          5.3          5.1      
   White                                     1133         4569         8031          10112         8957          5263         2779     
   %                                         82.0         82.1         78.7          80.1          79.7          81.1         79.6     
   Other[1](#t1-fn1){ref-type="fn"}          172          715          1540          1650          1493          815          512      
   %                                         12.4         12.7         15.1          13.1          13.3          12.6         14.7     
   Unknown                                    23          100           151           160           139           71           25      
   %                                         1.7          1.8           1.5           1.3           1.2          1.1          0.7      
  Sex                                                                                                                                  
   Male                                      222          824          1822          2605          2813          1861         1009       0.001
   %                                         16.1         14.6         17.9          20.6          25.0          28.7         28.9     
   Female                                    1160         4802         8385          10019         8424          4631         2482     
   %                                         83.9         85.4         82.1          79.4          75.0          71.3         71.1     
  Grade[2](#t1-fn2){ref-type="fn"}                                                                                                     
   I/II                                      270          1151         1946          2313          1985          1132         585        0.001
   %                                         19.5         20.5         19.1          18.3          17.7          17.4         16.7     
   III/IV                                     13           30           50            92            96           105          126      
   %                                         0.9          0.5           0.5           0.7           0.9          1.6          3.6      
   Unknown                                   1099         4445         8211          10219         9156          5255         2782     
   %                                         79.5         79.0         80.4          80.9          81.5          80.9         79.6     
  Histology                                                                                                                            
   Papillary                                 1273         5247         9693          12005         10628         6074         3166       0.001
   %                                         92.1         93.3         95.0          95.1          94.6          93.6         90.6     
   Follicular                                109          379           514           619           609          418          327      
   %                                         7.9          6.7           5.0           4.9           5.4          6.4          9.4      
  Summary Stage                                                                                                                        
   Regional/ Localized                       1325         5497         10016         12377         10908         6181         3138       0.001
   %                                         95.9         97.7         98.1          98.0          97.1          95.2         89.8     
   Distant                                    54          107           163           222           304          295          337      
   %                                         3.9          1.9           1.6           1.8           2.7          4.5          9.6      
   Unknown                                    3            22           28            25            25            16           18      
   %                                         0.2          0.4           0.3           0.2           0.2          0.2          0.5      
  AJCC 7^th^ TNM Stage                                                                                                                 
   I/II                                      1355         5532         10051         9888          7328          4217         1946       0.001
   %                                         98.0         98.3         98.5          78.3          65.2          65.0         55.7     
   III/IV                                     --           --           --           2231          3303          1916         1315     
   %                                          --           --           --           17.7          29.4          29.5         37.6     
   Unclassified                               27           94           156           505           606          359          232      
   %                                         2.0          1.7           1.5           4.0           5.4          5.5          6.6      
  Radiation[3](#t1-fn3){ref-type="fn"}                                                                                                 
   Yes                                       886          3338         5699          6671          5633          3134         1553       0.001
   %                                         64.1         59.3         55.8          52.8          50.1          48.3         44.5     
   No                                        469          2174         4347          5778          5414          3270         1878     
   %                                         33.9         38.6         42.6          45.8          48.2          50.4         53.8     
   Unknown                                    27          114           161           175           190           88           62      
   %                                         2.0          2.0           1.6           1.4           1.7          1.4          1.8      
  Vital Status                                                                                                                         
   Overall Death                              4            22           54            164           292          338          565        0.001
   %                                         0.3          0.4           0.5           1.3           2.6          5.2          16.2     
   Alive                                     1378         5604         10153         12460         10945         6154         2928     
   %                                         99.7         99.6         99.5          98.7          97.4          94.8         83.8     

^1^Including American Indian/AK Native, Asian/Pacific Islander.

^2^Grade I, well differentiated; Grade II, moderately differentiated; Grade III, poorly differentiated; Grade IV, undifferentiated; anaplastic.

^3^Including radioisotopes, radioactive implants, beam radiation, and combination of beam with implants or isotopes.

LGAbbreviations: DTC, differentiated thyroid cancer.

###### Univariate and multivariate survival analyses of DTCs according to various clinicopathological variables.

  Variable                                No. Case   Overall Survival   Cancer-specific Survival                                                                         
  -------------------------------------- ---------- ------------------ -------------------------- --------- ----------- ----------- ---------- ------- ----- ----------- ---
  Race                                                                                                                                                                   
   Black                                    2651          17.864                 0.001               1.0     Reference                17.488    0.001   1.0   Reference    
   White                                   40844           0.7                 00.6--0.9           0.0--01      1.1      0.7--1.7     0.797                              
   Other[1](#t2-fn1){ref-type="fn"}         6897           0.6                  0.5--0.8            0.001       1.1      0.7--1.8     0.773                              
   Unknown                                  669            0.2                  0.1--0.7            0.007       --          --          --                               
  Sex                                                                                                                                                                    
   Male                                    11156         264.902                 0.001               1.0     Reference               120.124    0.001   1.0   Reference    
   Female                                  39905           0.6                  0.6--0.7            0.001       0.7      0.6--0.9     0.002                              
  Age                                                                                                                                                                    
   ≤20                                      1382         3188.966                0.001               1.0     Reference               1168.245   0.001   1.0   Reference    
   21--30                                   5626           1.4                  0.5--4.1            0.534       1.1      0.1--10.1    0.915                              
   31--40                                  10207           1.9                  0.7--5.1            0.232       1.4      0.2--11.1    0.748                              
   41--50                                  12624           3.7                 1.4--10.1            0.009       2.4      0.3--17.6    0.389                              
   51--60                                  11237           6.7                 2.5--18.0            0.001       4.4      0.6--32.2    0.140                              
   61--70                                   6492           12.4                4.6--33.4            0.001       7.5      1.0--54.1    0.047                              
   ≥71                                      3493           33.4                12.5--89.7           0.001      13.5      1.9--97.8    0.010                              
  Grade[2](#t2-fn2){ref-type="fn"}                                                                                                                                       
   I/II                                     9382         2082.423                0.001               1.0     Reference               4545.199   0.001   1.0   Reference    
   III/IV                                   512            5.0                  4.0--6.2            0.001       9.4      6.8--13.0    0.001                              
   Unknown                                 41167           1.0                  0.9--1.2            0.783       1.1      0.8--1.5     0.562                              
  Histology                                                                                                                                                              
   Papillary                               48086          47.526                 0.001               1.0     Reference                46.145    0.001   1.0   Reference    
   Follicular                               2975           1.1                  0.9--1.3            0.219       1.2      0.9--1.5     0.231                              
  Summary Stage                                                                                                                                                          
   Regional/Localized                      49442                                                     1.0     Reference               4425.317   0.001   1.0   Reference    
   Distant                                  1482           3.6                  3.1--4.1            0.001       7.6      6.2--9.4     0.001                              
   Unknown                                  137            1.3                  0.6--2.8            0.508       4.8      2.0--11.4    0.001                              
  AJCC 7^th^ Stage                                                                                                                                                       
   I/II                                    40317         1206.620                0.001               1.0     Reference               1378.796   0.001   1.0   Reference    
   III/IV                                   8765           1.8                  1.6--2.0            0.001       5.5      4.0--7.5     0.001                              
   Unclassified                             1979           1.9                  1.5--2.3            0.001       4.8      3.2--7.2     0.001                              
  Radiation[3](#t2-fn3){ref-type="fn"}                                                                                                                                   
   No                                      26914          2.761                  0.251               1.0     Reference                48.602    0.001   1.0   Reference    
   Yes                                     23330           1.3                  1.1--1.4            0.001       0.9      0.7--1.1     0.232                              
   Known                                    817            1.3                  0.9--2.0            0.194       0.8      0.4--1.8     0.651                              

^1^Including American Indian/AK Native, Asian/Pacific Islander.

^2^Grade I, well differentiated; Grade II, moderately differentiated; Grade III, poorly differentiated; Grade IV, undifferentiated; anaplastic.

^3^Including radioisotopes, radioactive implants, beam radiation, and combination of beam with implants or isotopes.

^4^HR is presented as risk of overall mortality when specific groups are compared with reference groups.

^5^HR is presented as risk of cancer-specific mortality when specific groups are compared with reference groups.

Abbreviations: DTC, differentiated thyroid cancer; HR, hazard ratio; CI, confidence interval.

[^1]: These authors contributed equally to this work.
